Short Seller Performance
Recent analysis of short interest data reveals that Regeneron Pharmaceuticals (Nasdaq: REGN) was among the stocks that generated the largest losses for short sellers during the September market rout. As the broader market declined, short interest increased across nearly all sectors, but specific names like REGN demonstrated the risks inherent in betting against high-quality pharmaceutical equities.
Sector-Wide Trends
Data from Ortex shows that aggregate short interest shares increased considerably in the energy and materials sectors during the same period, with energy seeing a 14.7% rise in shorted shares. Regeneron's performance serves as a reminder that even in a high-short-interest environment, price action can quickly turn against bearish positions, leading to forced covering and potential squeeze events.
Signal data sourced from Ortex. This post is an original analysis prepared by The Forensic Ledger from publicly available data. Not investment advice.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.